Beam Therapeutics Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · Cambridge, MA
BEAM chart
What traders are saying about $BEAM
Latest postsBeam Therapeutics Inc. news
- H.C. Wainwright reiterates Buy on Beam Therapeutics stock on trial data
Investing.com ·
- Beam Therapeutics (BEAM) Dropped, So What Is Behind The Latest Attention?
Simply Wall St ·
- Beam Therapeutics (BEAM) Clears A Key Trial As The Undervalued Case Faces A Test
Yahoo Finance ·
- Beam Therapeutics (BEAM) Shares Fall Despite Positive Sickle Cel
GuruFocus ·
- Beam Therapeutics ($BEAM): Historic Moment. Pivotal Data Clears the Path for the World’s First Base Editing BLA Filing.
Simply Wall St ·
- Beam’s base editing therapy for sickle cell hits goal in pivotal trial
biopharmadive.com ·
- Beam Therapeutics to seek approval of SCD cell therapy after trial success
clinicaltrialsarena.com ·
- Beam Therapeutics Announces Positive Topline
Moomoo ·
- Beam Therapeutics at guggenheim healthcare conference: pipeline builds By Investing.com
Investing.com UK ·
- Beam Therapeutics Inc. (BEAM) Stock Price, News, Quote & History
Yahoo! Finance Canada ·
- Beam Therapeutics Reports Positive Pivotal Data for Risto-cel in Sickle Cell Disease
TradingView ·
- Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease
Yahoo Finance ·
Beam Therapeutics Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $139.7M | $63.5M | $377.7M | $60.9M |
| Net income | -$80.0M | -$376.7M | -$132.5M | -$289.1M |
| Diluted EPS | $-0.81 | $-4.58 | $-1.72 | $-4.13 |
| Total assets (year end) | $1.48B | $1.10B | $1.46B | $1.34B |
| Cash and equivalents (year end) | $294.9M | $282.0M | $435.9M | $232.8M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Beam Therapeutics Inc.
- Ticker
- BEAM (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Cambridge, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1745999
- Former names
- Beam Therapeutics Inc.
Frequently asked questions
What exchange is Beam Therapeutics Inc. listed on?
Beam Therapeutics Inc. trades on the Nasdaq under the ticker symbol BEAM.
What industry is Beam Therapeutics Inc. in?
Beam Therapeutics Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Beam Therapeutics Inc. headquartered?
Beam Therapeutics Inc.'s business address on file with the SEC is in Cambridge, MA.
When does Beam Therapeutics Inc.'s fiscal year end?
Beam Therapeutics Inc.'s fiscal year ends on December 31.
How much revenue did Beam Therapeutics Inc. report?
Beam Therapeutics Inc. reported $139.7M in revenue for calendar year 2025, according to its SEC filings.